Abu Suleiman, A.; Quagliariello, V.; Spadafora, L.; Russo, F.; Maurea, N.
Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence. Pharmaceuticals 2026, 19, 833.
https://doi.org/10.3390/ph19060833
AMA Style
Abu Suleiman A, Quagliariello V, Spadafora L, Russo F, Maurea N.
Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence. Pharmaceuticals. 2026; 19(6):833.
https://doi.org/10.3390/ph19060833
Chicago/Turabian Style
Abu Suleiman, Amro, Vincenzo Quagliariello, Luigi Spadafora, Federico Russo, and Nicola Maurea.
2026. "Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence" Pharmaceuticals 19, no. 6: 833.
https://doi.org/10.3390/ph19060833
APA Style
Abu Suleiman, A., Quagliariello, V., Spadafora, L., Russo, F., & Maurea, N.
(2026). Cardiovascular Toxicity of Novel HER2-Targeted Agents and Multikinase Inhibitors in Oncology: From Mechanisms to Real-World Clinical Evidence. Pharmaceuticals, 19(6), 833.
https://doi.org/10.3390/ph19060833